CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to LLY

IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)

Phase 2
Eli Lilly and Company (LLY)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Hepatocellular Carcinoma

View Full Landscape
Drug Information

Target Indication

Hepatocellular Carcinoma

Clinical Trial

NCT00906373

Last updated: 1/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.